Beta Drugs Intrinsic Value
Beta Drugs intrinsic value. Beta Drugs (BETA) median intrinsic value is ₹776.00 from 9 valuation models (range ₹490–₹1002), vs current price ₹2004.00 — -61.3% downside (Trading Above Calculated Value), margin of safety -100.0%. Compare with BETA fair value estimate to assess whether the stock is under or overvalued.
BETA Valuation Methods Summary — DCF, Graham Number & P/E
Beta Drugs intrinsic value across 9 models vs current price ₹2004.00 — upside/downside and value range per method. For current market price and key ratios, visit BETA share price screener.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹785.84 | ₹628.67 - ₹943.01 | -60.8% | EPS: ₹35.72, Sector P/E: 22x |
| Book Value Method | asset | ₹490.00 | ₹441.00 - ₹539.00 | -75.5% | Book Value/Share: ₹245.00, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹776.00 | ₹698.40 - ₹853.60 | -61.3% | Revenue/Share: ₹388.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹840.00 | ₹756.00 - ₹924.00 | -58.1% | EBITDA: ₹84.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹801.60 | ₹641.28 - ₹961.92 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹601.20 | ₹541.08 - ₹661.32 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹601.20 | ₹541.08 - ₹661.32 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1002.00 | ₹901.80 - ₹1102.20 | -50.0% | ROE: 14.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹601.20 | ₹541.08 - ₹661.32 | -70.0% | EPS: ₹35.72, BVPS: ₹245.00 |
BETA Intrinsic Value vs Market Price — All Valuation Models
Beta Drugs fair value range ₹490–₹1002 vs current market price ₹2004.00 across 9 valuation models. Read BETA dividend growth for the complete payout history and dividend yield track record.
BETA Intrinsic Value Analysis — Undervalued or Overvalued?
Beta Drugs median intrinsic value ₹776.00, current price ₹2004.00 — Trading Above Calculated Value by 61.3%, margin of safety -100.0%.
What is the intrinsic value of BETA?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Beta Drugs (BETA) is ₹776.00 (median value). With the current market price of ₹2004.00, this represents a -61.3% variance from our estimated fair value.
The valuation range spans from ₹490.00 to ₹1002.00, indicating ₹490.00 - ₹1002.00.
Is BETA undervalued or overvalued?
Based on our multi-method analysis, Beta Drugs (BETA) appears to be trading above calculated value by approximately 61.3%.
BETA Financial Health — Key Ratios vs Industry Benchmarks
Beta Drugs financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 2.34 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 19.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.78x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
BETA Cash Flow Quality — Operating & Free Cash Flow
Beta Drugs operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹36 Cr | ₹18 Cr | Positive Free Cash Flow | 7/10 |
| March 2024 | ₹31 Cr | ₹24 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹23 Cr | ₹14 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹30 Cr | ₹19 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹19 Cr | ₹16 Cr | Positive Free Cash Flow | 8/10 |